Metabo-epigenetic circuits of heart failure: chromatin-modifying enzymes as determinants of metabolic plasticity
Metabolic adaptations are a functional requirement for the heart to accommodate its broad range of physiologic operating conditions. It is increasingly recognized that persistent and exaggerated metabolic alterations precede adverse cardiac remodeling leading to heart failure. These metabolic shifts...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
11 December 2025
|
| In: |
EMBO molecular medicine
Year: 2025, Pages: 1-19 |
| ISSN: | 1757-4684 |
| DOI: | 10.1038/s44321-025-00343-y |
| Online Access: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.1038/s44321-025-00343-y Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1038/s44321-025-00343-y 
|
| Author Notes: | Mark E Pepin, Xuemin Gong, Almut Schulze & Johannes Backs |
| Summary: | Metabolic adaptations are a functional requirement for the heart to accommodate its broad range of physiologic operating conditions. It is increasingly recognized that persistent and exaggerated metabolic alterations precede adverse cardiac remodeling leading to heart failure. These metabolic shifts are coupled with changes in cardiac gene expression, driven in part by chromatin-modifying enzymes, which have recently been identified as both sensors and transducers of metabolic stress and gene regulatory networks, respectively. This review synthesizes the latest evidence implicating chromatin-modifying enzymes as key regulators of metabolic reprogramming in the heart, providing a framework to understand how metabolic stressors are incorporated as epigenetic modifications that regulate cardiac gene expression. We propose a model of ‘metabo-epigenetic circuitry’ within which energy metabolic perturbations drive transcriptional and epigenetic changes that ultimately contribute to cardiac dysfunction. Although many nodes in these circuits remain unidentified, this viewpoint opens new avenues for investigating chromatin-modifying enzymes as therapeutic targets to halt the metabolic programs that promote heart failure. |
|---|---|
| Item Description: | Gesehen am 14.01.2026 |
| Physical Description: | Online Resource |
| ISSN: | 1757-4684 |
| DOI: | 10.1038/s44321-025-00343-y |